APA (7th ed.) Citation

M, D., A, M., S, K., CM, B., H, G., N, N., . . . D, Z. (2025). Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison. Advances in therapy, 42(6), 2690. https://doi.org/10.1007/s12325-025-03144-4

Chicago Style (17th ed.) Citation

M, Dzienis, et al. "Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison." Advances in Therapy 42, no. 6 (2025): 2690. https://doi.org/10.1007/s12325-025-03144-4.

MLA (9th ed.) Citation

M, Dzienis, et al. "Pembrolizumab with Carboplatin and Paclitaxel Versus Alternative Systemic Treatments Recommended for the First-Line Treatment of Recurrent/Metastatic Head and Neck Cancer: An Indirect Treatment Comparison." Advances in Therapy, vol. 42, no. 6, 2025, p. 2690, https://doi.org/10.1007/s12325-025-03144-4.